Abstract This large community-based cohort study investigates the impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), specifically Liraglutide and Semaglutide, on the risk of developing psychiatric conditions such as depression, anxiety, and suicidal behaviors in patients with obesity
4-9 We trawled through studies to compare the results, with the findings as follows: Liraglutide (Saxenda): 63.2% of study participants lost at least 5% body weight
Injection Requirement Most GLP-1 medications are administered via injection, which may be a barrier for patients who are uncomfortable with needles or prefer oral medications
Research on blackcurrant powder points to a more targeted approach, supporting circulation, energy utilization, and recovery rather than nervous system stimulation
JORGE, PURCHASING MANAGER Interested